I think RACE have focused on Melanoma and Renal Cancer initially due to potential to pair it with the PD-1 inhibitors.
Given the speed at which Merck achieved approvals for Keytruda ( over 30 in 7 years ), Big Pharma will ultimately be the ones to have the best crack at accelerating approvals for indications like Pancreatic Cancer (subject to successful trials of course).
The RAC 3-Pillar Trifecta, page-194
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.88 |
Change
0.025(1.35%) |
Mkt cap ! $319.4M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.89 | $1.85 | $74.38K | 39.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18943 | $1.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.88 | 199 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |